Category Archives: Global News Feed

ISELIN, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced recent corporate highlights and financial results for its fiscal second quarter ended March 31, 2022.

Excerpt from:
Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate Update

POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled.

Read the rest here:
POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update

Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in Europe Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in Europe

Read the original post:
Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines &...

PGX Technology continues to demonstrate ability to generate novel bioactive delivery systems for nutraceuticals, drug delivery and wound healing PGX Technology continues to demonstrate ability to generate novel bioactive delivery systems for nutraceuticals, drug delivery and wound healing

Originally posted here:
Ceapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids

FREMONT, CA, May 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced it has engaged the FreeMind Group to help ABVC explore and identify funding opportunities from non-dilutive sources, such as the NIH, DOD, NSF, FDA and BARDA, as well as private foundations.

View post:
ABVC BioPharma Engages the FreeMind Group to Support Grant Funding

Phase 3 study of LB1148 in lead indication for postoperative return of bowel function on track to commence Q2 2022

Originally posted here:
Palisade Bio Reports First Quarter 2022 Financial Results and Provides Corporate Update

BUFFALO, N.Y., May 13, 2022 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated to improving human health with reduced nicotine tobacco, hemp/cannabis, and hops advanced plant technology, today announced the acquisition of privately held GVB Biopharma. As a contract development and manufacturing organization (CDMO), GVB is believed to be one of the largest providers of hemp-derived active ingredients for the pharmaceutical and consumer goods industries worldwide based on total tonnage.

Read this article:
22nd Century Group (Nasdaq: XXII) Acquires GVB Biopharma, a Leading Hemp/Cannabis Company

NEW YORK, May 13, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that, GBS’s 2022 Annual Meeting of Shareholders will be held in a virtual-only meeting format via live audio webcast. The Company’s proxy statement describing the formal business to be conducted at the meeting is available on the Investors section of the Company’s website at: https://www.cstproxy.com/gbs/2022 Please see additional details below:

Read more here:
GBS Inc. to Hold Virtual 2022 Annual Shareholder Meeting on Thursday, June 16, 2022, at 4:00pm ET

TORONTO, Ontario and CAMBRIDGE, Massachusetts, May 13, 2022 (GLOBE NEWSWIRE) -- There was an error at the end of the first paragraph. March 31, 2021 has been changed to March 31, 2022. There were no other changes to the release. Please find full corrected release below.

Read the original:
CORRECTION: ProMIS Neurosciences Announces First Quarter 2022 Results

Clearmind aims to initiate clinical trials with CMND-100 by year’s end

View post:
Clearmind Announces Pre-IND Meeting Date with FDA